Persila V. Mertz, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 115 E Main St, Ephrata, PA 17522 Phone: 717-733-3600 Fax: 717-721-3038 |
News Archive
QLT Inc. today announced that QLT091001, an oral synthetic retinoid, has received positive opinions for two distinct Orphan Drug Designations by the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) for the treatment of the inherited retinal degenerative diseases, Leber Congenital Amaurosis (LCA) and Retinitis Pigmentosa (RP).
Electronic cigarettes should be evaluated, regulated, labeled and packaged in a manner consistent with cartridge content and product effect - even if that effect is a total failure to deliver nicotine as demonstrated in a study supported by the National Cancer Institute and led by a Virginia Commonwealth University researcher.
The Huntington's Disease Regulatory Science Consortium, launched in March 2018 by the Critical Path Institute and CHDI Foundation, today, along with the Clinical Data Interchange Standards Consortium, announce the open availability of a newly developed Huntington's Disease Therapeutic Area User Guide
The extent to which protein targets are modulated by drugs or small molecule compounds depends on a number of factors, including the expression levels of the target, the effective concentration of the compound, and the time needed for the compound to perturb the target. To address these restrictions, researchers Abassi et al. (1) have devised a live cell morphological profiling approach for dynamic monitoring of the effect of small molecule compounds that was based on impedance measurement of cells with the xCELLigence RTCA System of Roche Applied Science.
› Verified 4 days ago